RxDoctor Payments Data

Shalabh Chandra, MD

Clinical Cardiac Electrophysiology · Gainesville, GANPI 1144343708

Payments from drug & device makers

$10,565in general payments, 2019–2025

Across 368 payments — averaging $28.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$2K
  • Boston Scientific$1K
  • Johnson & Johnson$723
  • Biosense Webster, Inc.$618
  • Novartis$594
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$1,41813%
  • Food & beverage$9,03686%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,565 in reported general payments places this provider in the 20th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$399,190
Medicare patients
1,639
Services billed
5,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban552$481,171
XareltoRivaroxaban107$122,029
EntrestoSacubitril/Valsartan59$57,022
FarxigaDapagliflozin Propanediol12$10,325
Flecainide Acetate252$9,797
Metoprolol Succinate551$7,676
SotalolSotalol Hcl362$5,093
Amiodarone Hcl201$4,665
Propafenone Hcl ErPropafenone Hcl16$2,561
Diltiazem 24hr Er (Cd)Diltiazem Hcl177$2,486
Propafenone Hcl35$781
Sotalol AfSotalol Hcl29$721
ClopidogrelClopidogrel Bisulfate99$568
Fludrocortisone Acetate18$541
Metoprolol Tartrate106$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$401$481,171552 claims
Johnson & JohnsonXarelto$723$122,029107 claims
NovartisEntresto$594$57,02259 claims
AstraZenecaFarxiga$81$10,32512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

Other clinical cardiac electrophysiology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →